
Novela Neurotech is a digital health company that creates personalized care for chronic neurological conditions. With a decade of research legacy in neurotechnology and epilepsy at the University of Waterloo in Canada, Novela is uniquely positioned to transform current episodic neurological care to remote care for millions of people with chronic neurological disorders. Their flagship product, Neureka for epilepsy, offers AI-powered health insights and instant alerts for critical health changes, aiming to improve treatment outcomes and quality of life for patients. The company is guided by the expertise and input from patients, caregivers, and neurologists, ensuring that their solutions meet the needs of an independent lifestyle.

Novela Neurotech is a digital health company that creates personalized care for chronic neurological conditions. With a decade of research legacy in neurotechnology and epilepsy at the University of Waterloo in Canada, Novela is uniquely positioned to transform current episodic neurological care to remote care for millions of people with chronic neurological disorders. Their flagship product, Neureka for epilepsy, offers AI-powered health insights and instant alerts for critical health changes, aiming to improve treatment outcomes and quality of life for patients. The company is guided by the expertise and input from patients, caregivers, and neurologists, ensuring that their solutions meet the needs of an independent lifestyle.
Headquarters: San Francisco, California, United States
Founded: 2018
Focus: Digital/neurotechnology for chronic neurological conditions (epilepsy flagship)
Team size (reported): 7 employees
Latest disclosed funding: Grant, Sep 2022
Chronic neurological conditions (epilepsy cited; targets include addiction, depression, Alzheimer’s, Parkinson’s in product framing).
2018
Medical technology / Digital health / Neurotechnology
“Ontario Brain Institute listed as an investor on aggregate databases”